Qsymia is FDA-approved for long-term use, with no set end date as long as it continues working and you tolerate it well. The longest clinical trial followed patients for 108 weeks (just over two years) and found the drug was well tolerated throughout, with side effects actually decreasing in the second year compared to the first. That said, there are specific checkpoints where your prescriber will evaluate whether the medication is worth continuing.
The 12-Week Checkpoints
Qsymia uses a “prove it works or stop” approach built into the prescribing guidelines. After your first 12 weeks on the mid-range dose, you need to have lost at least 3% of your starting body weight. If you haven’t hit that mark, your prescriber will either increase your dose or discuss stopping the medication.
If you move up to the highest dose, the bar goes higher. After another 12 weeks at that level, you need to have lost at least 5% of your starting body weight. If you haven’t, the FDA label recommends discontinuing the drug entirely, because it’s unlikely you’ll achieve meaningful weight loss by continuing. These aren’t arbitrary numbers. They’re based on clinical trial data showing that early response predicts long-term success.
What “Long-Term” Looks Like in Practice
The SEQUEL extension study, published in the American Journal of Clinical Nutrition, is the best data available on sustained Qsymia use. Participants who stayed on the drug for 108 weeks lost an average of 9.3% of their body weight on the mid-range dose and 10.5% on the highest dose, compared to just 1.8% for those taking a placebo. Importantly, that weight loss held steady through the second year rather than rebounding.
Side effects were also more manageable over time. Adverse events occurred at lower rates between weeks 56 and 108 than during the first 56 weeks. This suggests the body adjusts to the medication rather than accumulating new problems, which is reassuring if you’re considering staying on it for a year or more.
Side Effects to Watch Over Time
The most common issue is tingling or numbness in your hands and feet, reported by about 14% of people on the mid-range dose and 20% on the highest dose during one-year trials. This is a known effect of the topiramate component and is generally harmless, though it can be annoying.
Cognitive side effects, like difficulty finding words or trouble concentrating, affected about 5% to 7.6% of people depending on the dose, compared to 1.5% on placebo. These tend to be mild but are worth flagging to your prescriber if they interfere with your daily life.
Kidney stones are a less common but real concern. In one-year trials, about 1.2% of people on the highest dose developed them, compared to 0.3% on placebo. Staying well hydrated helps reduce this risk. The topiramate in Qsymia can also lower bicarbonate levels in your blood, a condition called metabolic acidosis. In most patients, bicarbonate levels dipped within the first four weeks after reaching their assigned dose but corrected on their own by week 56 without needing a dose change.
Ongoing Monitoring While You’re on It
Staying on Qsymia long-term means regular lab work and check-ins. Before starting and periodically throughout treatment, your prescriber will check your kidney function, potassium levels, and blood bicarbonate. If you have type 2 diabetes, blood sugar monitoring is also part of the routine, since weight loss can change how your body responds to diabetes medications. If you take blood pressure medication, expect that to be tracked as well.
Heart rate monitoring is recommended for everyone on Qsymia, especially when starting or increasing the dose. For people who can become pregnant, monthly pregnancy tests are required because topiramate carries a risk of birth defects.
How to Stop Safely
You should not stop Qsymia abruptly if you’re on the highest dose. The topiramate component can trigger seizures during sudden withdrawal, even in people who have never had seizures before. The recommended taper is to take the highest dose every other day for at least one week before stopping completely. If you’re on a lower dose, the seizure risk is smaller, but it’s still worth discussing the plan with your prescriber rather than simply running out of pills.
For Adolescents Ages 12 and Older
Qsymia is approved for patients 12 and older, with the same general timeline but using BMI reduction instead of pounds lost as the benchmark. After 12 weeks, a teen needs at least a 3% reduction in baseline BMI to stay on the mid-range dose, or 5% on the highest dose. Pediatric guidelines from the Pediatric Endocrine Society recommend discontinuing if BMI continues to climb at the full dose after three to four months, or if side effects become problematic. As with adults, tapering is necessary before stopping.